Bengaluru: HCG, a leading Indian cancer care provider, has partnered with Trucan Diagnostics to develop and validate innovative cancer diagnostic tests. This collaboration seeks to enhance early cancer detection, predict treatment outcomes, and monitor disease progression effectively.
As part of this partnership, HCG and Trucan will conduct extensive validation studies on a new suite of cancer diagnostic tests developed by Trucan. These tests utilize advanced techniques such as next-generation sequencing and biomarker-driven diagnostics, enabling precise detection of primary, recurrent, and metastatic cancers, pre-treatment prediction of therapy response, and monitoring of patients undergoing chemotherapy or targeted therapies. The validation studies will provide essential data to confirm the clinical utility of these tests, facilitating their integration into routine clinical practice.
By accurately predicting patients’ responses to therapy, these diagnostic tests aim to empower oncologists to personalize treatment plans, reduce ineffective therapies, minimize associated morbidity, and lower overall treatment costs.
Dr.B.S.Ajaikumar, Executive Chairman, Healthcare Global Enterprises Limited, said, “ By validating next-generation diagnostic tools developed in our Genomics laboratory at Triesta Sciences, we aim not only to enhance detection but also to deliver highly personalised treatment plans tailored to each patient’s unique cancer profile.”
